Abstract：
BACKGROUND: Breast cancer treatments often have negative effects on fertility, which pose challenges among patients who want to be parents in the future. This study aimed to examine the efficacy of oocyte cryopreservation, embryo cryopreservation, and ovarian tissue cryopreservation in patients with breast cancer.
METHODS: This retrospective review evaluated 42 patients with breast cancer who underwent fertility preservation at our center from January 2012 to December 2022. This review encompassed the demographic characteristics of the patients, cancer stages, treatment details, and types of fertility preservation procedures and their outcomes.
RESULTS: The average age at disease diagnosis was 33.4 years. Approximately 90.4% of patients presented with early-stage cancer (≤2). Of 42 patients, 26 underwent oocyte cryopreservation; 17, embryo cryopreservation; and 2, ovarian tissue cryopreservation. Further, three patients received mixed treatment. The overall live birth rate was 63.2%. There are more live births in embryo cryopreservation group. The successful pregnancy group was significantly younger and had a remarkably higher quantity of preserved oocytes/embryos than the nonsuccessful pregnancy group. The oocyte and embryo utilization rates in cryopreservation were 7.69% and 52.94%, respectively. These findings underscored the importance of prompt, informed discussions about fertility preservation options.
CONCLUSIONS: Fertility preservation in patients with breast cancer have promising reproductive outcomes, with embryo cryopreservation being particularly effective. Prompt counseling and individualized fertility preservation strategies are important for improving the likelihood of posttreatment pregnancy. Nevertheless, future research on the long-term psychological and emotional effects of different fertility preservation methods must be performed.
METHODS: This retrospective review evaluated 42 patients with breast cancer who underwent fertility preservation at our center from January 2012 to December 2022. This review encompassed the demographic characteristics of the patients, cancer stages, treatment details, and types of fertility preservation procedures and their outcomes.
RESULTS: The average age at disease diagnosis was 33.4 years. Approximately 90.4% of patients presented with early-stage cancer (≤2). Of 42 patients, 26 underwent oocyte cryopreservation; 17, embryo cryopreservation; and 2, ovarian tissue cryopreservation. Further, three patients received mixed treatment. The overall live birth rate was 63.2%. There are more live births in embryo cryopreservation group. The successful pregnancy group was significantly younger and had a remarkably higher quantity of preserved oocytes/embryos than the nonsuccessful pregnancy group. The oocyte and embryo utilization rates in cryopreservation were 7.69% and 52.94%, respectively. These findings underscored the importance of prompt, informed discussions about fertility preservation options.
CONCLUSIONS: Fertility preservation in patients with breast cancer have promising reproductive outcomes, with embryo cryopreservation being particularly effective. Prompt counseling and individualized fertility preservation strategies are important for improving the likelihood of posttreatment pregnancy. Nevertheless, future research on the long-term psychological and emotional effects of different fertility preservation methods must be performed.
摘要：
背景：乳腺癌治疗通常会对生育能力产生负面影响，这对将来想成为父母的患者构成了挑战。这项研究旨在检查卵母细胞冷冻保存的功效，胚胎冷冻保存,和卵巢组织冷冻保存在乳腺癌患者。
方法：这项回顾性研究评估了2012年1月至2022年12月在我们中心接受生育能力保留的42例乳腺癌患者。这篇综述涵盖了患者的人口统计学特征，癌症阶段，治疗细节,以及生育力保存程序的类型及其结果。
结果：疾病诊断的平均年龄为33.4岁。约90.4%的患者出现早期癌症（≤2）。42名患者中,26例进行了卵母细胞冷冻保存；17，胚胎冷冻保存；和2，卵巢组织冷冻保存。Further,3例患者接受混合治疗.总体活产率为63.2%。胚胎冷冻保存组中活产较多。成功妊娠组比未成功妊娠组显着年轻，并且保存的卵母细胞/胚胎数量显着高于未成功妊娠组。冷冻保存的卵母细胞和胚胎利用率分别为7.69%和52.94%,分别。这些发现强调了迅速，关于生育力保护选项的知情讨论。
结论：保留乳腺癌患者的生育力具有良好的生殖结局，胚胎冷冻保存特别有效。及时的咨询和个性化的生育保护策略对于提高治疗后妊娠的可能性很重要。然而，未来必须对不同生育力保存方法的长期心理和情绪影响进行研究。
方法：这项回顾性研究评估了2012年1月至2022年12月在我们中心接受生育能力保留的42例乳腺癌患者。这篇综述涵盖了患者的人口统计学特征，癌症阶段，治疗细节,以及生育力保存程序的类型及其结果。
结果：疾病诊断的平均年龄为33.4岁。约90.4%的患者出现早期癌症（≤2）。42名患者中,26例进行了卵母细胞冷冻保存；17，胚胎冷冻保存；和2，卵巢组织冷冻保存。Further,3例患者接受混合治疗.总体活产率为63.2%。胚胎冷冻保存组中活产较多。成功妊娠组比未成功妊娠组显着年轻，并且保存的卵母细胞/胚胎数量显着高于未成功妊娠组。冷冻保存的卵母细胞和胚胎利用率分别为7.69%和52.94%,分别。这些发现强调了迅速，关于生育力保护选项的知情讨论。
结论：保留乳腺癌患者的生育力具有良好的生殖结局，胚胎冷冻保存特别有效。及时的咨询和个性化的生育保护策略对于提高治疗后妊娠的可能性很重要。然而，未来必须对不同生育力保存方法的长期心理和情绪影响进行研究。
